SUMMIT (Serially Unified Multicenter Multiple Sclerosis Investigation): creating a repository of deeply phenotyped contemporary multiple sclerosis cohorts

No abstract is available for this paper.

• Publication year

  2018

• Venue

  Multiple Sclerosis

• Publication date

  2018-10-01

• Fields of study

  Medicine

• Identifiers
  DOI 10.1177/1352458517726657PMID 28847219PMCID PMC5821573
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Serum lipid antibodies are associated with cerebral tissue damage in multiple sclerosis

  2016cited by this paper
• Power estimation for non-standardized multisite studies

  2016cited by this paper
• Predictors of long‐term disability accrual in relapse‐onset multiple sclerosis

  2016cited by this paper
• Genes and Environment in Multiple Sclerosis project: A platform to investigate multiple sclerosis risk

  2016cited by this paper
• The Framingham Heart Study — 67 years of discovery in metabolic disease

  2016cited by this paper
• Long‐term evolution of multiple sclerosis disability in the treatment era

  2016cited by this paper
• Steering through complexity: management approaches in multiple sclerosis.

  2016cited by this paper
• 2D phase‐sensitive inversion recovery imaging to measure in vivo spinal cord gray and white matter areas in clinically feasible acquisition times

  2015cited by this paper
• Inclusion of brain volume loss in a revised measure of ‘no evidence of disease activity’ (NEDA-4) in relapsing–remitting multiple sclerosis

  2015cited by this paper
• Evaluation of no evidence of disease activity in a 7-year longitudinal multiple sclerosis cohort.

  2015cited by this paper
• Defining high, medium and low impact prognostic factors for developing multiple sclerosis.

  2015cited by this paper
• Age, Gender and Normalization Covariates for Spinal Cord Gray Matter and Total Cross-Sectional Areas at Cervical and Thoracic Levels: A 2D Phase Sensitive Inversion Recovery Imaging Study

  2015cited by this paper
• Whole Brain Volume Measured from 1.5T versus 3T MRI in Healthy Subjects and Patients with Multiple Sclerosis

  2015cited by this paper
• Association Between Thoracic Spinal Cord Gray Matter Atrophy and Disability in Multiple Sclerosis.

  2015cited by this paper
• Disease activity free status: a new end point for a new era in multiple sclerosis clinical research?

  2014cited by this paper
• Spinal cord gray matter atrophy correlates with multiple sclerosis disability

  2014cited by this paper
• Precision medicine in chronic disease management: The multiple sclerosis BioScreen

  2014cited by this paper
• Tob1 plays a critical role in the activation of encephalitogenic T cells in CNS autoimmunity

  2013cited by this paper
• Analysis of immune-related loci identifies 48 new susceptibility variants for multiple sclerosis

  2013cited by this paper
• Fine-Mapping the Genetic Association of the Major Histocompatibility Complex in Multiple Sclerosis: HLA and Non-HLA Effects

  2013cited by this paper
• Circulating MicroRNAs as biomarkers for disease staging in multiple sclerosis

  2013cited by this paper
• Clinical and MRI predictors of response to interferon‐beta and glatiramer acetate in relapsing–remitting multiple sclerosis patients

  2013cited by this paper
• The Relationships among MRI‐Defined Spinal Cord Involvement, Brain Involvement, and Disability in Multiple Sclerosis

  2012cited by this paper
• Effect of gender on late-onset multiple sclerosis

  2012cited by this paper
• An RNA Profile Identifies Two Subsets of Multiple Sclerosis Patients Differing in Disease Activity

  2012cited by this paper
• Genome‐wide meta‐analysis identifies novel multiple sclerosis susceptibility loci

  2011cited by this paper
• Relationship between early clinical characteristics and long term disability outcomes: 16 year cohort study (follow-up) of the pivotal interferon β-1b trial in multiple sclerosis

  2011cited by this paper
• HLA B*44: Protective effects in MS susceptibility and MRI outcome measures

  2011cited by this paper
• Genetic risk and a primary role for cell-mediated immune mechanisms in multiple sclerosis

  2011cited by this paper
• HLA B*44

  2010cited by this paper
• Rapid semi-automatic segmentation of the spinal cord from magnetic resonance images: Application in multiple sclerosis

  2010cited by this paper
• New perspectives in the natural history of multiple sclerosis

  2010cited by this paper
• Thalamic damage and long-term progression of disability in multiple sclerosis.

  2010cited by this paper
• The Multiple Sclerosis Functional Composite

  2010cited by this paper
• Integration of genetic risk factors into a clinical algorithm for multiple sclerosis susceptibility: a weighted genetic risk score.

  2009cited by this paper
• Modification of Multiple Sclerosis Phenotypes by African Ancestry at HLA.

  2009cited by this paper
• Pathway and network-based analysis of genome-wide association studies in multiple sclerosis

  2009cited by this paper
• Real‐life impact of early interferonβ therapy in relapsing multiple sclerosis

  2009cited by this paper
• Gray matter atrophy correlates with MS disability progression measured with MSFC but not EDSS.

  2009cited by this paper
• One‐year MRI scan predicts clinical response to interferon beta in multiple sclerosis

  2009cited by this paper
• Gray matter atrophy correlates with MS disability progression measured with MSFC but not EDSS.

  2009cited by this paper
• Gray matter atrophy in multiple sclerosis: A longitudinal study

  2008cited by this paper
• Abrogation of T cell quiescence characterizes patients at high risk for multiple sclerosis after the initial neurological event

  2008cited by this paper
• Natural history of multiple sclerosis in a population‐based cohort

  2008influential reference
• New natural history of interferon-beta-treated relapsing multiple sclerosis.

  2007cited by this paper
• New natural history of interferon‐β–treated relapsing multiple sclerosis

  2007cited by this paper
• Thalamic atrophy and cognition in multiple sclerosis

  2007cited by this paper
• アルツハイマー病の早期診断に向けて-米国 Alzheimer's Disease Neuroimaging Initiative の取り組み

  2006cited by this paper
• A model for the comprehensive investigation of a chronic autoimmune disease: the multiple sclerosis CLIMB study.

  2006cited by this paper
• MSBase: an international, online registry and platform for collaborative outcomes research in multiple sclerosis

  2006cited by this paper
• Disability progression in multiple sclerosis is slower than previously reported

  2006cited by this paper
• The Alzheimer's disease neuroimaging initiative.

  2005cited by this paper
• The natural history of primary progressive MS in British Columbia, Canada

  2005cited by this paper
• Disability profile of MS did not change over 10 years in a population-based prevalence cohort

  2004cited by this paper
• Early clinical predictors and progression of irreversible disability in multiple sclerosis: an amnesic process.

  2003influential reference
• HLA-DR 15 is associated with female sex and younger age at diagnosis in multiple sclerosis

  2002cited by this paper
• A longitudinal study of abnormalities on MRI and disability from multiple sclerosis.

  2002cited by this paper
• A LONGITUDINAL STUDY OF ABNORMALITIES ON MRI AND DISABILITY FROM MULTIPLE SCLEROSIS

  2002cited by this paper
• Recommended diagnostic criteria for multiple sclerosis: Guidelines from the international panel on the diagnosis of multiple sclerosis

  2001cited by this paper
• Relapses and progression of disability in multiple sclerosis.

  2000influential reference
• HLA‐DR15 is associated with lower age at onset in multiple sclerosis

  2000cited by this paper
• The natural history of multiple sclerosis: a geographically based study. 2. Predictive value of the early clinical course.

  1989cited by this paper
• The natural history of multiple sclerosis: a geographically based study. I. Clinical course and disability.

  1989cited by this paper
• A proportional hazards model for interval-censored failure time data.

  1986cited by this paper
• Epidemiological approaches to heart disease: the Framingham Study.

  1951cited by this paper

• Predictors of Radiological and Clinical Disease Reactivation in Multiple Sclerosis Patients After Cessation of Natalizumab (Tysabri)

  2025cites this paper
• Clinical Validation of a Multi-protein, Serum-based Assay for Disease Activity Assessments in Multiple Sclerosis

  2023cites this paper
• Early miR-320b and miR-25-3p miRNA levels correlate with multiple sclerosis severity at 10 years: a cohort study

  2023cites this paper
• Challenges to Longitudinal Characterization of Lower Urinary Tract Dysfunction in Multiple Sclerosis.

  2022cites this paper
• Subtypes of relapsing-remitting multiple sclerosis identified by network analysis

  2022cites this paper
• Characterisation of MS phenotypes across the age span using a novel data set integrating 34 clinical trials (NO.MS cohort): Age is a key contributor to presentation

  2021cites this paper
• Temporal trends of multiple sclerosis disease activity: Electronic health records indicators.

  2021cites this paper
• The Canadian prospective cohort study to understand progression in multiple sclerosis (CanProCo): rationale, aims, and study design

  2021cites this paper
• Oral contraceptives do not modify the risk of a second attack and disability accrual in a prospective cohort of women with a clinically isolated syndrome and early multiple sclerosis

  2021cites this paper
• The North American Registry for Care and Research in Multiple Sclerosis (NARCRMS).

  2021cites this paper
• Serum antibodies to phosphatidylcholine in MS

  2020cites this paper
• Monitoring of radiologic disease activity by serum neurofilaments in MS

  2020cites this paper
• Brain MRI Predicts Worsening Multiple Sclerosis Disability over 5 Years in the SUMMIT Study

  2020cites this paper
• Ensemble learning predicts multiple sclerosis disease course in the SUMMIT study

  2020cites this paper
• Head-to-head drug comparisons in multiple sclerosis

  2019cites this paper
• Silent progression in disease activity–free relapsing multiple sclerosis

  2019cites this paper
• Association of Rituximab Treatment With Disability Progression Among Patients With Secondary Progressive Multiple Sclerosis

  2019cites this paper
• An evolutionary approach

  2018cites this paper
• Complexity of MS management in the current treatment era

  2018cites this paper
• Serum neurofilament as a predictor of disease worsening and brain and spinal cord atrophy in multiple sclerosis

  2018cites this paper